Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD₆₅-induced immune response.

ABSTRACT:

Aims/hypothesis

A European Phase III trial of GAD formulated with aluminium hydroxide (GAD-alum) failed to reach its primary endpoint (preservation of stimulated C-peptide secretion from baseline to 15 months in type 1 diabetes patients), but subgroup analysis showed a clinical effect when participants from Nordic countries were excluded, raising concern as to whether the mass vaccination of the Swedish and Finnish populations with the Pandemrix influenza vaccine could have influenced the study outcomes. In the current study, we aimed to assess whether Pandemrix vaccination affects the specific immune responses induced by GAD-alum and the C-peptide response.

Methods

In this secondary analysis, we analysed data acquired from the Swedish participants in the Phase III GAD-alum

SUBMITTER: Tavira B 

PROVIDER: S-EPMC5487599 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature